PIK3CA and neoplasm: A study on the use of BYL719 in combination with paclitaxel to treat HER2− metastatic breast cancer found that patients with tumor/ctDNA mutations experienced better PFS when compared with patients without PIK3CA mutations, and that PFS was also higher in patients with normal metabolism [92].